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Abstract
The neurotrophic hypothesispostulates that mood disorderssuch asbipolar disorder (BD) are associated
with a lower expression of brain-derived neurotrophic factor (BDNF).However, its role in peripheral blood asa biomarker
of disease activity and of stage for BD, transcending pathophysiology, isstill disputed. In the last few yearsan increasing
number of clinical studiesassessing BDNFin serum and plasma have been published. Therefore, it isnow possible to
analyse the association between BDNFlevelsand the severity of affective symptomsin BD aswell as the effectsof acute
drug treatment of mood episodeson BDNFlevels.
We conducted a systematic review and meta-analysisof all studieson serum and plasma BDNFlevels in
bipolar disorder.
Through a series of meta-analyses including a total of 52 studies with 6,481 participants, we show
that, compared to healthy controls,peripheral BDNFlevelsare reduced to the same extent in manic (Hedges’ g= −0.57,
P= 0.010) and depressive (Hedges’ g = −0.93, P= 0.001) episodes, while BDNF levels are not significantly altered in
euthymia. In meta-regression analyses, BDNFlevelsadditionally negatively correlate with the severity of both manic and
depressive symptoms. We found no evidence for a significant impact of illnessduration on BDNFlevels. In addition, in
plasma, but not serum, peripheral BDNFlevels increase after the successful treatment of an acute mania episode, but not
of adepressive one.
In summary, our data suggest that peripheral BDNFlevels, more clearly in plasma than in serum, isa
potential biomarker of disease activity in BD, but not a biomarker of stage. We suggest that peripheral BDNFmay, in
future, be used asa part of a blood protein composite measure to assessdisease activity in BD.
Biomarker, Bipolar disorder, Brain-derived neurotrophic factor, Meta-analysis
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Table 1 Statistics on between-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
Between-group N of pairwise Number of subjects Meta-Analysis Heterogeneity
BD Controls Hedges’ g 95 % CI Pvalue I2 Q Pvalue
Mania
Mania vs. HC– all* 19 605 792 −0.57 −0.99 −0.14 0.010 92.07 239.69 0.001
Mania vs. HC–
drug-naïve or free*
6 175 186 −0.66 −1.14 −0.10 0.020 79.43 29.17 0.001
Mania vs. HC– medicated 14 430 628 −0.54 −1.09 0.00 0.051 92.71 178.41 0.001
Mania vs. HC– serum* 12 288 512 −0.97 −1.41 −0.53 0.001 86.45 81.12 0.001
Mania vs. HC– plasma 6 206 188 −0.03 −0.98 0.95 0.951 94.73 94.94 0.001
Mania vs. HC– plasma
Barbosa excluded*
4 124 92 −0.72 −1.27 −0.17 0.001 70.06 10.02 0.018
Mania vs. HC– whole-
blood
2 144 153 0.12 −0.11 0.35 0.296 N/A N/A N/A
Mania vs. HC–
age-/sex-matched
14 488 551 −0.46 −0.99 0.07 0.073 93.09 202.40 0.001
Mania vs. HC–
not age-/sex-matched*
5 117 241 −0.84 −1.51 −0.18 0.042 86.17 28.90 0.001
Depression
Depression vs. HC – all* 15 352 722 −0.93 −1.37 −0.50 0.001 87.88 107.27 0.001
Depression vs. HC –
drug-naïve or free*
3 47 210 −1.24 −1.88 −0.61 0.001 64.24 5.59 0.061
Depression vs. HC –
medicated*
13 305 534 −0.90 −1.59 −0.55 0.001 88.40 95.51 0.001
Depression vs. HC –
serum*
12 305 519 −0.72 −1.17 −0.27 0.002 87.53 114.67 0.001
Depression vs. HC –
plasma*
3 47 203 −1.94 −3.38 −0.49 0.009 90.25 20.51 0.001
Depression vs. HC –
age-/sex-matched*
10 245 501 −0.81 −1.29 −0.35 0.001 82.26 45.11 0.001
Depression vs. HC – not
age-/sex-matched*
5 107 221 −1.23 −2.30 −0.17 0.023 93.18 58.73 0.001
Depression vs. HC – only
BD type I*
12 219 369 −1.27 −1.80 −0.72 0.001 86.05 71.70 0.001
Euthymia
Euthymia vs. HC – all 24 1598 1459 0.05 −0.13 0.24 0.569 81.19 122.29 0.001
Euthymia vs. HC – serum 16 980 1022 −0.04 −0.16 0.17 0.689 86.67 69.66 0.001
Euthymiavs. HC– plasma 8 618 437 0.26 −0.12 0.65 0.626 86.67 52.51 0.001
Euthymia vs. HC –
age-/sex-matched
16 658 733 0.02 −0.29 0.33 0.894 87.41 119.19 0.001
Euthymia vs. HC – not
age-/sex-matched
7 919 700 −0.06 −0.40 0.26 0.702 88.18 50.75 0.001
Euthymia vs. HC – only
BD type I
16 631 757 0.01 −0.30 0.32 0.319 87.00 115.43 0.001
Euthymia vs. HC – only
BD type II
2 31 48 −0.36 −1.46 0.73 0.729 81.66 5.45 0.001
Mixed State
Mixed state vs. HC – all 3 44 169 0.09 −0.57 0.75 0.787 69.14 6.48 0.039
Moderators between-group N of pairwise Number of subjects Meta-regression Meta-regression
BD Controls Slope 95 % CI Pvalue Intercept Z Pvalue
Mania
Table 1 Statistics on between-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
(Continued)
Age of BD patients – all* 19 605 792 0.07 0.02 0.13 0.005 −3.41 −3.27 0.001
Age of BD patients –
Barbosa excluded
17 523 696 0.03 −0.03 0.10 0.305 −1.93 −1.54 0.123
Age of controls – all 19 605 792 0.04 −0.01 0.01 0.165 −2.14 −1.85 0.064
Age difference(BD-HC) – all* 19 605 792 0.18 0.05 0.31 0.004 −0.61 −3.15 0.001
Age difference(BD-HC) –
Barbosa excluded
17 523 696 0.08 −0.07 0.24 0.295 −0.74 −3.86 0.001
%Females (Patients)– all 17 579 760 0.01 −0.01 0.04 0.288 −1.33 −1.76 0.076
%Females (HC) – all 17 579 760 0.00 −0.02 0.02 0.811 −0.75 −0.96 0.332
Difference in
%females (BD-HC) – all
17 579 760 0.02 −0.01 0.05 0.250 −0.54 −2.25 0.023
Mean illness duration
(years) – all
13 481 568 0.10 −0.01 0.21 0.070 −1.60 −2.27 0.023
Sample size– all 19 605 792 0.00 −0.00 0.01 0.126 −1.09 −2.68 0.009
YMRSscores – all* 17 583 750 −0.09 −0.15 −0.03 0.004 2.44 2.33 0.019
YMRSscores – plasma* 5 192 176 −0.09 −0.16 −0.01 0.017 2.96 2.47 0.013
YMRSscores – serum 10 247 421 −0.07 −0.15 0.00 0.052 1.63 1.18 0.235
Depression
Age of BD patients – all 14 346 702 0.01 −0.04 0.06 0.681 −1.41 −1.21 0.225
Age of controls – all 14 346 702 0.00 −0.06 0.07 0.996 −1.00 −0.76 0.445
Age difference(BD-HC) – all 14 346 702 0.08 −0.07 0.24 0.262 −1.22 −3.99 0.001
%Females (HC) – all 14 346 702 −0.00 −0.02 0.01 0.850 −1.03 −1.62 0.104
%Females (Patients) – all 14 346 702 0.00 −0.01 0.01 0.782 −1.28 −2.30 0.020
Difference in %females
(BD-HC) – all
14 346 702 0.02 −0.01 0.05 0.193 −0.95 −3.68 0.001
Mean illness duration
(years) – all*
5 103 359 −0.14 −0.20 −0.07 0.001 −2.47 3.44 0.001
Sample size – all 15 352 722 0.00 −0.00 0.01 0.070 −1.60 −3.74 0.001
Year of publication – all 15 352 722 0.03 −0.14 0.19 0.726 −61.80 −0.35 0.722
HDRSscores – all* 13 311 609 −0.23 −042 −0.04 0.018 4.40 1.93 0.053
HDRSscores – serum 11 274 427 −0.12 −0.35 0.09 0.265 1.70 0.60 0.542
Euthymia
Age of BD patients – all 24 1598 1459 −0.00 −0.02 0.02 0.950 0.11 0.23 0.831
Age of controls – all 24 1598 1459 −0.00 −0.02 0.01 0.802 0.16 0.36 0.712
Age difference(BD-HC) – all 24 1598 1459 0.02 −0.06 0.11 0.537 0.04 0.41 0.676
%Females (HC) – all 23 1425 1197 0.00 −0.01 0.01 0.878 −0.03 −0.05 0.995
%Females (Patients) – all 23 1425 1197 0.00 −0.01 0.02 0.690 −0.26 −0.40 0.684
Difference in %females
(BD-HC) – all
23 1425 1197 0.01 −0.02 0.03 0.555 0.06 0.68 0.495
Number of mood
episodes – all
5 206 220 0.01 −0.05 0.06 0.833 −0.24 −0.58 0.557
Illnessduration (years)–all 13 831 696 0.01 −0.02 0.05 0.577 0.01 0.01 0.992
Illness duration (years) –
excluding Barbosa 2010,
2012, 2013
10 739 575 −0.01 −0.04 0.02 0.496 0.13 0.48 0.630
Sample size – all 24 1598 1459 −0.00 −0.01 0.01 0.530 0.12 0.85 0.390
− − −
−
− −
Fig. 1 Forest plots of between-group meta-analyses measuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjects with bipolar
disorder compared to healthy controls, separated by mood state and medication status. ( ) Mania, studies separated according use of medication.
( ) Depression, studies separated according use of medication. The sizes of the circles are proportional to the sample size. Circles depict individual
studies and diamonds depict the pooled effect sizes. Serum and plasma BDNF levels were decreased in subjects with bipolar disorder in mania
and depression on and off psychiatric medication when compared to healthy controls
− − −
− − −
−
− − − − −
− −
Fig. 2 Forest plots of between-group meta-analysis measuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjects with bipolar
disorder in euthymia compared to healthy controls.All studiesreferred to personson psychiatric medication. The sizesof the circlesare proportional to
the sample size. Circlesdepict individual studiesand diamondsdepict the pooled effect size. Serum and plasmaBDNFlevelswere not altered in persons
with bipolar disorder in euthymiawhen compared to healthy controls
Fig. 3 ( ) Direct comparison of the effect sizes of the different studies in mania, depression, and euthymia. Peripheral brain-derived neurotrophic
factor (BDNF) levels were equally decreased in mania and depression (P= 0.340), and both manic and depressive states presented BDNF levels
decreased when compared to euthymic state (P= 0.002). ( ) Meta-regression of the effect sizes of peripheral BDNF levels against severity of
mania as assessed by the Young Mania Rating Scale (YMRS) scores, showing more accentuated decreases in BDNF levels with increase in YMRS
scores (P= 0.004). ( ) Meta-regression of the effect sizes of peripheral BDNF levels against severity of depression as assessed by the Hamilton
Depression Rating Scale (HDRS) scores, showing more accentuated decreasesin BDNFlevelswith increase in HDRSscores(P= 0.018). ( ) Meta-regression
of the effect sizesof peripheral BDNFlevelsagainst duration of illness in years in euthymic subjects, showing no association between BDNFlevelsand
duration of bipolar illness in yearsduring euthymia (P= 0.577)
Fig. 4 Forest plotsof within-group meta-analysesmeasuring peripheral brain-derived neurotrophic factor (BDNF) levels in subjectswith bipolar disorder
before and after treatment for an index acute manic or depressive mood episode. ( ) Mania studiesgrouped according the source of the blood sample.
All studiespresented response to the manic episode after pharmacological treatment,asdefined asa decrease of at least 50 %on the Young ManiaRating
Scale scores.PlasmaBDNFlevels increased after successful treatment of an index manic episode.Serum BDNFlevelsremained unchanged. ( ) Depression
studiesgrouped according the source of the blood sample.Serum and plasma BDNFlevelsremained unchanged after treatment of an index depressive
episode. ( ) Depression studiesgrouped according response or non-response to pharmacological treatment of the acute depressive episode,defined asa
decrease of at least 50 %on the Hamilton Depression Rating Scale scores.Serum and plasmaBDNFlevelsremained unchanged after treatment of an index
depressive episode regardless of response or non-response to treatment. The sizes of the circles are proportional to the sample size. Circles
depict individual studies and diamonds depict the pooled effect sizes
−Table 2 Statistics on within-group meta-analyses regarding peripheral brain-derived neurotrophic factor levels in bipolar disorder
Within-Group N of pairwise Number of subjects Meta-analysis Heterogeneity
Hedges’ g 95 % CI Pvalue I2 Q Pvalue
Mania
Mania– all* 13 556 0.26 0.09 0.45 0.003 69.69 39.60 0.001
Serum and plasma* 12 454 0.30 0.08 0.44 0.005 78.48 18.59 0.001
Serum 5 122 0.39 −0.03 0.81 0.065 78.48 18.59 0.001
Plasma* 7 332 0.23 0.02 0.44 0.028 55.20 13.39 0.037
Whole blood 1 102 0.01 −0.19 0.20 0.941 N/A N/A N/A
Depression
Depression – all 8 184 0.05 −0.28 0.38 0.747 76.51 29.79 0.001
Depression – except Mackin 2007 [71] 7 164 0.15 −0.18 0.49 0.364 72.84 22.09 0.001
Serum 5 88 −0.12 −0.52 0.29 0.563 72.15 14.36 0.006
Plasma 3 96 0.40 −0.40 1.21 0.329 85.93 14.22 0.001
Response 3 115 −0.06 −0.24 0.18 0.492 N/A N/A N/A
Non-response 5 69 0.13 −0.53 0.79 0.702 85.69 1.51 0.001
Moderators within-group N of pairwise Number of subjects Meta-regression Meta-regression
Slope 95 % CI Pvalue Intercept Z Pvalue
Mania
Age of BD Patients – all 9 456 −0.01 −0.04 0.02 0.398 0.80 1.39 0.165
% Females – all 13 556 0.01 −0.03 0.02 0.478 0.07 0.27 0.782
Baseline YMRSscores 12 542 0.01 −0.01 0.02 0.930 0.20 0.63 0.522
Difference in YMRS(After – Before) 12 542 −0.01 −0.02 0.02 0.298 0.16 1.42 0.155
% Change in YMRSScores 12 542 −0.01 −0.02 0.01 0.213 0.77 1.73 0.083
Follow-up duration (weeks) 13 556 0.01 −0.01 0.03 0.396 0.19 1.63 0.101
Year of publication 13 556 −0.07 −0.12 −0.01 0.011 141.63 2.53 0.011
Depression
Age of BD patients – all 6 164 −0.01 −0.05 0.02 0.393 0.50 0.69 0.489
% Females – all* 6 164 0.01 0.00 0.02 0.042 −0.54 −2.29 0.021
% Females – excluding Mackin 2007 [71] 5 144 0.01 −0.01 0.01 0.555 −0.20 −0.68 0.490
Baseline HDRSscores 8 184 0.02 −0.18 0.22 0.823 −0.42 −0.19 0.845
Difference in HDRS(After – Before) 7 164 −0.02 −0.09 0.06 0.658 −0.01 −0.01 0.988
% Change in HDRSscores 7 164 0.01 −0.01 0.02 0.566 −0.05 −0.13 0.892
Follow-up duration (weeks) 8 184 0.01 −0.05 0.07 0.673 −0.04 −0.12 0.899
Year of publication 8 184 0.01 −0.11 0.11 0.987 −1.76 −0.01 0.988
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Addit ional files
Addit ional file 1: PRISMA flowchart of the meta-analytic re-
view. Forest plot for random effects between-group meta-
analysis of peripheral BDNF levels in participants with bipolar disorder on
a mixed episode. Sensitivity analysis of included studies in
between-group meta-analyses of peripheral BDNF levels in participants
with bipolar disorder in mania. Sensitivity analysis of included
studies in between-group meta-analyses of peripheral BDNF levels in par-
ticipants with bipolar disorder in depression. Sensitivity ana-
lysis of included studies in between-group meta-analyses of peripheral
BDNF levels in participants with bipolar disorder in euthymia.
Sensitivity analysis of included studies in within-group meta-analyses of
peripheral BDNF levels in participants with bipolar disorder in mania.
Sensitivity analysis of included studies in within-group meta-
analyses of peripheral BDNF levels in participants with bipolar disorder in
depression. Cumulative Meta-Analysis of included studies in
between-group meta-analyses of peripheral BDNF levels in participants
with mania. Cumulative Meta-Analysis of included studies in
between-group meta-analyses of peripheral BDNF levels in participants
with depression. Cumulative Meta-Analysis of included stud-
ies in between-group meta-analyses of peripheral BDNF levels in partici-
pants with euthymia. Cumulative Meta-Analysis of included
studies in within-group meta-analyses of peripheral BDNF levels in partici-
pants with bipolar disorder in mania. Cumulative Meta-
Analysis of included studies in within-group meta-analyses of peripheral
BDNF levels in participants with bipolar disorder in depression.
Funnel plot of included studies in between-group meta-analyses of
peripheral BDNF levels in participants with bipolar disorder in mania com-
pared to healthy controls. The white diamond shows the observed
summary effect size. The black diamond shows the adjusted effect size
after the trim and fill procedure. Funnel plot of included
studies in between-group meta-analyses of peripheral BDNF levels in par-
ticipants with bipolar disorder in depression compared to healthy con-
trols. Funnel plot of included studies in between-group
meta-analyses of peripheral BDNF levels in participants with bipolar dis-
order in euthymia compared to healthy controls. Funnel plot
of included studies in within-group meta-analyses of peripheral BDNF
level in participants with bipolar disorder in mania before and after treat-
ment. Funnel plot of included studies in within-group meta-
analyses of peripheral BDNF levels in participants with bipolar disorder in
depression before and after treatment. (PDF 567 kb)
Addit ional file 2: Studies excluded in secondary screening
(with reasons). Characteristics of studies included in between-
group meta-analyses of peripheral BDNF levels in bipolar disorder, across
different mood states. Characteristics of studies included in
within-group meta-analyses of peripheral BDNF levels in bipolar disorder
across different mood states. Characteristics of meta-analyses
of peripheral BDNF in bipolar disorder. Assessment of bias
across meta-analyses of peripheral BDNF in bipolar disorder. (PDF 690 kb)
BD: Bipolar disorder; BDNF: Brain-derived neurotrophic factor; CI: Confidence
interval; ES: Effect size; HDRS: Hamilton Depression Rating Scale;
PRISMA: Preferred Reporting Itemsfor Systematic Reviewsand Meta-Analyses;
YMRS:Young Mania Rating Scale.
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